Tandem Diabetes Care received 510(k) clearance for Tandem Mobi’s tubeless cartridge and infusion set, supporting up to 7 days of wear and 3 days of cartridge use. U.S. launch is planned for the first half of 2027.
TNDM · Tandem Diabetes Care Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Tandem reported worldwide revenue grew 14% year-over-year to $284 million, announced a CEO retirement at the end of 2026 and named Jeanette Bankus president and CEO.
Tandem Diabetes Care reported third-quarter sales of $283.7 million, including $92.6 million internationally, and a 57% gross margin, compared with $249.3 million and 54%, amid continued inventory constraints from a key supplier.
Tandem Diabetes Care reported third-quarter sales of $283.7 million, up 14%, gross margin of 57% and an operating loss of $2.4 million versus $22.9 million. Adjusted EBITDA reached $18.0 million, compared with $2.8 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Tandem delivered 14% worldwide sales growth, a 57% gross margin and positive adjusted EBITDA, while reaffirming 2026 guidance and advancing Mobi Tubeless toward approval. The main offsets were slower pharmacy adoption extending revenue headwinds into 2027, a mid-to-high-single-digit 2027 revenue-growth starting point, continued operating losses, infusion-set shortages and international transition headwinds.
- + Worldwide sales grew 14% year over year to $283.7 million.
- + Gross margin reached 57%, up 270 basis points from the prior-year quarter.
- + Adjusted EBITDA reached 6% of sales, marking the fifth consecutive quarter of positive adjusted EBITDA.
- + The company reaffirmed its 2026 guidance, including worldwide sales of approximately $1.065 billion to $1.085 billion.
- + Pharmacy formulary coverage reached approximately 50% of U.S. lives, achieving the year-end access goal early.
- + Mobi Tubeless remained in the late stages of FDA review and was expected to be approved in the fourth quarter, followed by limited customer use and expanded commercial availability in the first half of 2027.
- − Pharmacy adoption scaled more gradually than initially anticipated because of the time required to establish prescription workflows and change behaviors.
- − Pharmacy pump adoption outpaced supply conversions, creating continued sales headwinds extending into 2027.
- − Management indicated that mid-to-high-single-digit year-over-year revenue growth was a reasonable starting point for 2027.
- − Tandem remained GAAP operating-loss-making, although the operating loss narrowed to $2.4 million from $22.9 million.
- − Infusion-set supply shortages continued to affect the business into early 2027 despite improving availability in the third quarter.
- − International direct-market transitions created a $3 million quarterly headwind and approximately $7 million of year-to-date impact.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $9.15M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA margin non-GAAP | 2% | Six Months Ended June 30, 2026 | — |
| Direct sales to customers as a percentage of international sales | 13% | the three months ended June 30, 2026 filing | — |
| International pump shipments | 11,000 | the three months ended June 30, 2026 filing | +22.2% |
|
|
|||
| Non-GAAP free cash flow non-GAAP | -$33.89M | Six Months Ended June 30, 2026 | — |
| Non-GAAP net loss non-GAAP | -$41.56M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating loss non-GAAP | -$31.23M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating margin non-GAAP | -6% | Six Months Ended June 30, 2026 | — |
| Pump shipments | 33,000 | second quarter 2026 | +266.7% |
|
|
|||
| Pump shipments in the United States | 22,000 | second quarter 2026 | +4.8% |
|
|
|||
| pumps shipped worldwide | 33,000 | the three months ended June 30, 2026 filing | — |
| Sales through the pharmacy channel as a percentage of United States sales | 10% | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNDM
this stock
Tandem Diabetes Care Inc
|
$1.40B | -8.7% | +7.9% | — | 23.2% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 18
Tandem Diabetes Care received 510(k) clearance for Tandem Mobi’s tubeless cartridge and infusion set, supporting up to 7 days of wear and 3 days of cartridge use. U.S. launch is planned for the first half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNDM | +18.7% | +23.6% | +38.0% | +5.0% | -8.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +16.1% | +24.7% | +37.5% | +5.2% | -19.3% |